scispace - formally typeset
M

Muthusamy Thangaraju

Researcher at Georgia Regents University

Publications -  94
Citations -  8235

Muthusamy Thangaraju is an academic researcher from Georgia Regents University. The author has contributed to research in topics: Cancer & Apoptosis. The author has an hindex of 43, co-authored 86 publications receiving 6791 citations. Previous affiliations of Muthusamy Thangaraju include McGill University & Mayo Clinic.

Papers
More filters
Journal ArticleDOI

Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis

TL;DR: This paper showed that GPR109a signaling promoted anti-inflammatory properties in colonic macrophages and dendritic cells and enabled them to induce differentiation of Treg cells and IL-10-producing T cells.
Journal ArticleDOI

Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond

TL;DR: This review focuses on three groups of nutrient transporters relevant to cancer: glucosetransporters, lactate transportters, and amino acid transporter, which are related to amino acid nutrition.
Journal ArticleDOI

GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon

TL;DR: It is shown that GPR109A mediates the tumor-suppressive effects of the bacterial fermentation product butyrate in colon and suppresses nuclear factor-kappaB activation in normal and cancer colon cell lines as well as in normal mouse colon.
Journal ArticleDOI

Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis.

TL;DR: Analysis of pattern of expression of hSSTR1-5 in normal human islet cells by quantitative double-label confocal fluorescence immunocytochemistry reveals predominant expression of SSTR1, SSTR2, and SSTR5 in human islets, which could be the basis for preferential insulin suppression by Sstr1-specific ligands and of glucagon inhibition by SStr2-selective compounds.